Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Technical Insights – Trailing Stops

Bell Direct
July 18, 2016

Market Update 18 July

Julia Lee
July 18, 2016

Market Update 15 July

Julia Lee
July 15, 2016

Market Update 14 July

Julia Lee
July 14, 2016

Market Update 13 July

Julia Lee
July 13, 2016

Market Update

Julia Lee
July 11, 2016

Market Update

Julia Lee
July 8, 2016

Market Update

Julia Lee
July 7, 2016

CEO Interview Series: India Fund

Bell Direct
July 7, 2016